share_log

Gregory Stuart Smith Purchases 3,500 Shares of ImmunoPrecise Antibodies Ltd (TSE:IPA) Stock

Gregory Stuart Smith Purchases 3,500 Shares of ImmunoPrecise Antibodies Ltd (TSE:IPA) Stock

格雷戈裏·斯圖爾特·史密斯購買了3500股免疫精抗體有限公司(多倫多證券交易所代碼:IPA)股票
Financial News Live ·  2022/09/23 20:21

ImmunoPrecise Antibodies Ltd (TSE:IPA – Get Rating) Director Gregory Stuart Smith purchased 3,500 shares of ImmunoPrecise Antibodies stock in a transaction dated Friday, September 23rd. The stock was bought at an average price of C$5.41 per share, with a total value of C$18,935.00. Following the acquisition, the director now directly owns 42,500 shares of the company's stock, valued at C$229,925.

免疫精製抗體有限公司(東京證券交易所代碼:IPA-GET評級)董事格雷戈裏·斯圖爾特·史密斯在一筆日期為9月23日(星期五)的交易中購買了3,500股免疫精製抗體股票。該股是以每股5.41加元的平均價格購買的,總價值為18,935.00加元。收購完成後,董事現在直接擁有該公司42,500股股票,價值229,925加元。

Gregory Stuart Smith also recently made the following trade(s):

格雷戈裏·斯圖爾特·史密斯最近還進行了以下交易:

Get
到達
ImmunoPrecise Antibodies
免疫精確化抗體
alerts:
警報:
  • On Monday, August 15th, Gregory Stuart Smith purchased 5,000 shares of ImmunoPrecise Antibodies stock. The stock was bought at an average price of C$6.93 per share, with a total value of C$34,670.00.
  • 8月15日,星期一,格雷戈裏·斯圖爾特·史密斯購買了5,000股免疫精抗體股票。該股是以每股6.93加元的平均價格購買的,總價值為34,670.00加元。

ImmunoPrecise Antibodies Price Performance

免疫精確型抗體的性價比

ImmunoPrecise Antibodies Company Profile

免疫精準抗體公司簡介

(Get Rating)

(獲取評級)

IPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The Company aims to transform the conventional, multi-vendor, product development model by bringing innovative and high-throughput, data-driven technologies to its partners, incorporating the advantages of diverse antibody repertoires with the Company's therapeutic antibody discovery suite of technologies, to exploit antibodies of broad epitope coverage, multiple antibody formats, valency and size, and to discover antibodies against multiple/rare epitopes.
IPA是一家創新驅動的技術平臺公司,支持其製藥和生物技術公司合作伙伴發現和開發針對所有類別疾病目標的新型治療性抗體。該公司的目標是轉變傳統的多供應商產品開發模式,為其合作伙伴帶來創新和高通量的數據驅動技術,將各種抗體譜系的優勢與公司的治療性抗體發現套裝技術結合起來,開發具有廣泛表位覆蓋、多種抗體格式、效價和大小的抗體,並發現針對多種/稀有表位的抗體。

Featured Articles

專題文章

  • Why Does Tesla Stock Remain Resilient?
  • Will Crowdstrike Get A Boost From Increased EPS Guidance?
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 為什麼特斯拉的股票保持彈性?
  • CrowdStrike是否會從增加每股收益指引中獲得提振?
  • 好市多盈利後價格疲軟是買入的好時機嗎?
  • 需要關注的2只半導體類股走勢逆轉
  • 小盤股的裁員是樓市的晴雨表嗎?

Receive News & Ratings for ImmunoPrecise Antibodies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoPrecise Antibodies and related companies with MarketBeat.com's FREE daily email newsletter.

每天收到關於免疫精準抗體的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對免疫精準抗體和相關公司的評級的每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論